

**Fiscal Impact**  
2<sup>nd</sup> Session of the 57<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>SB 1467</b>
<b>Version:</b>	<b>INT</b>
<b>Author:</b>	<b>Sen. David</b>
<b>Date:</b>	<b>02/18/2022</b>

**Fiscal Analysis**

SB 1467 has OHCA conduct an annual review of all medications and treatment for sickle cell disease. OHCA believes an outside vendor would be needed to review the treatment aspects, this contract would have an estimated cost of \$400,000.00 of which half would be paid by the state.

**FY'23 Impact:** Approximately \$200,000.00

**Full Year Impact:** Approximately \$200,000.00

Prepared by: Oklahoma Health Care Authority